FDA ▶ Regulatory submissions

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (2019)

  Back

https://uploads-ssl.webflow.com/65dc93ef0a9b2f3705d0635e/6602a2735188c84b93bf7c67_novartis.png

https://clinicaltrials.gov/study/NCT03988634

Read also



Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (2019)
FDA
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (2019)
READ MORE →
 Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery (2023)
FDA
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery (2023)
READ MORE →
 Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (2019)
FDA
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (2019)
READ MORE →
 CardiAMP™ Cell Therapy for Heart Failure Trial (2016)
FDA
CardiAMP™ Cell Therapy for Heart Failure Trial (2016)
READ MORE →